semaglutide vs tirzepatide for diabetes Comparative safety and side effects of and tirzepatide: Implications clinical decision-making in obesity management 💉 Semaglutide vs. Tirzepatide —

This is exactly what researchers are exploring with compounds that target GLP-1, GIP, and glucagon receptors

8.5 Geriatric Use In the pool of seven clinical trials, 1539 (30.1%) MOUNJARO-treated patients were 65 years of age or older, and 212 (4.1%) MOUNJARO-treated patients were 75 years of age or older at baseline

Both act on GLP-1 receptors, and combining them greatly increases the risk of severe GI side effects, hypoglycemia (in diabetes patients), and other adverse events, without providing additional clinical benefit

Addressing these lifestyle factors often breaks plateaus without dose adjustments

Texas Health and Human Services